Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Thumbnail Image Read more about Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Affimed Announces Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer Thumbnail Image Read more about Affimed Announces Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
BioInvent to hold two poster presentations at SITC 38th Annual Meeting Thumbnail Image Read more about BioInvent to hold two poster presentations at SITC 38th Annual Meeting
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023 Thumbnail Image Read more about ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients Thumbnail Image Read more about Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory CTCL and PTCL Thumbnail Image Read more about Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory CTCL and PTCL
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with ALLONK® for the Treatment of Patients with Relapsed/Refractory Hodgkin Lymphoma Thumbnail Image Read more about Affimed Receives FDA Fast Track Designation for AFM13 in Combination with ALLONK® for the Treatment of Patients with Relapsed/Refractory Hodgkin Lymphoma
Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS Thumbnail Image Read more about Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL Thumbnail Image Read more about Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
